Singapore Science Park

MUST Connect 2023 Singapore highlighted the cutting-edge innovations of Korean life science startups

Retrieved on: 
Monday, October 16, 2023
Research, Clinical Trials, Health Technology, Professional Services, Start-Up, Biotechnology, Pharmaceutical, Health, Science, Other Professional Services, Partnership, Multimedia, Hospital, MUST, JLab Audio, Incheon Free Economic Zone, Entrepreneurship, Investment, Biomedical sciences, Singapore Science Park, Innovation, Accelerator, Celltrion, Connect, Speech, Assistant, Attention, CHC, J&J, Cryptocurrency, Film industry

MUST Connect 2023 Singapore, a roadshow that helps Korean life science startups expand overseas by connecting them with global pharmaceutical companies and investors, was held on Oct. 11 (Wed.) and 12 (Thu.)

Key Points: 
  • MUST Connect 2023 Singapore, a roadshow that helps Korean life science startups expand overseas by connecting them with global pharmaceutical companies and investors, was held on Oct. 11 (Wed.) and 12 (Thu.)
  • The Incheon Free Economic Zone (IFEZ), which has been supporting Korean life science startups, participated as a sponsoring organization.
  • "Korean life science startups are gaining increasing attention with each passing year,” observed Julia Lee, CEO of MUST Accelerator.
  • Many leading pharmaceutical companies have their APAC headquarters in Singapore and are actively seeking out promising life science startups in Asia.

Hummingbird Bioscience Holds Opening Ceremony for Singapore Science Park Office and Research Facilities

Retrieved on: 
Friday, September 23, 2022
Traction, Capital, Engineering, Immunoglobulin G, Efficiency, Singapore Science Park, Risk, Assistant, Biomedical Research, Aries, Growth, Enterprise Singapore, Investment, Cancer, Technology, Systems biology, Galen Cranz, HER3, Pharmacology, NUST School of Mechanical and Manufacturing Engineering, Genomics, Research, Translation, SEEDS, Drug discovery, Microbiology, Mass spectrometry, Oncology, Economy, Pharmaceutical industry, Fine chemical, Medical imaging

SINGAPORE, Sept. 23, 2022 /PRNewswire/ --Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the official opening of its office and research facilities at the Singapore Science Park.

Key Points: 
  • SINGAPORE, Sept. 23, 2022 /PRNewswire/ --Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the official opening of its office and research facilities at the Singapore Science Park.
  • "This is a significant milestone for the Hummingbird Bioscience team, which has come a long way since the company's inception in 2015," said Piers Ingram, Ph.D., Chief Executive Officer and co-founder of Hummingbird Bioscience.
  • The pharmacology, mass spectrometry, analytical science, production, genomics, discovery, engineering, and microbiology labs will further enable the Hummingbird Bioscience team to accelerate its biotherapeutics research.
  • At Hummingbird Bioscience, our commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic.

Proteintech Group Inc. opens new Singapore office

Retrieved on: 
Tuesday, July 5, 2022
Health, Genetics, Other Science, General Health, Research, Science, Biotechnology, Single-domain antibody, Singapore Science Park, CEO, Biotechnology, Protein, Research, International Business Park, ISO9001, Lion, Tuas Biomedical Park, Cytokine, ISO13485, Publication, Proteome, Hay Group Global R&D Center for Strategy Execution, Antibody, Multimedia, Retail, Fine chemical

Proteintech, the benchmark in antibodies, Nanobodies, and cytokines & growth factors, today announces the opening of its new Singapore office and warehouse at The Strategy, 2 International Business Park.

Key Points: 
  • Proteintech, the benchmark in antibodies, Nanobodies, and cytokines & growth factors, today announces the opening of its new Singapore office and warehouse at The Strategy, 2 International Business Park.
  • View the full release here: https://www.businesswire.com/news/home/20220705005683/en/
    The new Proteintech Singapore team (Photo: Business Wire)
    With its new office, Proteintech can better serve and support customers in the fast-growing APAC market.
  • Establishing the new office in Singapore puts dedicated resources to the fast-growing APAC countries.
  • Proteintech Group Inc., founded in 2002, is a leading manufacturer of antibodies, proteins, Nanobodies, and immunoassays.

Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

Retrieved on: 
Thursday, May 12, 2022
HBV, Research, Initiate, International Conference on Emerging Infectious Diseases, U.S. Securities and Exchange Commission, European Association for the Study of the Liver, Assembly, Cirrhosis, AO, ICAR, Conference, Virus, Chhattisgarh Special Public Security Act, SEC, Annual report, Annual general meeting, Incidence, COVID-19, Singapore Science Park, SAN, Securities Act of 1933, Degenerative disease, Antiviral Research, GLOBE, Inflammation, DNA, Doctor of Philosophy, 2021 Essex County Council election, ILC, Association, C1-inhibitor, Hepatitis B virus, Therapy, Securities Exchange Act of 1934, MD, Patient, EASL, Treatment, Sumathi Best Television Current Reporting Award, VBR, HDV, Liver disease, Liver cancer, Safety, HBeAg, Vaccine, Pharmaceutical industry, Mineral wool, Renewable energy, Cryptocurrency, Liver

SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today reported financial results and recent highlights for the first quarter ended March 31, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today reported financial results and recent highlights for the first quarter ended March 31, 2022.
  • Announced the expansion of Assembly Bios pipeline to include candidates focused on viruses outside of HBV.
  • Initiated triple combination study with VBR + NrtI and ATI-2173, Antios Therapeutics investigational active site polymerase inhibitor nucleotide (ASPIN).
  • More information about Assembly Bios risks and uncertainties are more fully detailed under the heading Risk Factors in Assembly Bios filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Allay Therapeutics Establishes Corporate Headquarters in the Bay Area and Expands Base of Operations in Singapore

Retrieved on: 
Thursday, January 6, 2022
Biotechnology, Surgery, Health, Pharmaceutical, Clinical Trials, Therapy, Growth, Research, Patient, Physician, Silicon, Analgesic, Lightstone, Biopolymer, Singapore Science Park, Foundry, Pain management, Pharmaceutical industry, San Francisco Bay Area, San Francisco Bay Area

Allay Therapeutics , a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced that it has established its corporate headquarters in San Jose, California and expanded its base of operations in Singapore.

Key Points: 
  • Allay Therapeutics , a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced that it has established its corporate headquarters in San Jose, California and expanded its base of operations in Singapore.
  • The 50,000 square foot Allay headquarters will accommodate Allays global workforce, which has nearly doubled over the last year, and its planned growth in the U.S. and Singapore.
  • Allay also doubled its Singapore footprint with the renewal and expansion of its R&D and operations facilities in the Singapore Science Park, a leading life sciences and innovation campus.
  • Allay unites a dynamic, global team of entrepreneurs, scientists, clinicians and innovators in the San Francisco Bay Area and Singapore.